P/B
4,8
AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
$243.4B
Market Cap • 10/2/2026
1992
(34 years)
Founded
NYSE
Listing Exchange
United Kingdom
Country
Valuation
P/S
4
P/EBITDA
12
P/OCF
17,8
P/FCF
22,8
P/E
23,5
BVPS
32,4
EPS
6,7
Market Cap
Market Cap
243,4B
EV
270,7B
EV/Revenue
4,4
EV/EBITDA
13,3
EV/EBIT
19,4
Payout
Dividend Per Share
3,2
Dividend Yield
2%
Buyback Yield
0,3%
Total Yield
2,3%
Dividend Yield 5Y
2%
Payout
46,9%
Retained Earnings
12,6B
Profitability
Gross Margin
81,9%
EBITDA Margin
33,1%
EBIT Margin
22,8%
Net Margin
17%
D&A/EBITDA
0%
R&D/Revenue
24,6%
Capex/Revenue
4,9%
Capex/D&A
47,7%
Capex/OCF
22,1%
SBC/OCF
—
% PPE
14,1%
% Goodwill
18,3%
ROE
22%
ROIC
12,6%
Growth
CAGR Revenue 5Y
15,8%
CAGR Op. Income 5Y
19,7%
CAGR Net Income 5Y
22,6%
CAGR EPS 5Y
18,4%
CAGR OCF 5Y
16,3%
Leverage
N.D./EBITDA
1,3
Debt/Equity
0%
Current Ratio
0,9
Quick Ratio
0,6
Interest Coverage
800,2%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!